| Followers | 20 |
| Posts | 7758 |
| Boards Moderated | 5 |
| Alias Born | 10/17/2022 |
Tuesday, August 26, 2025 8:31:10 AM
https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html
Recent ALLR News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:02:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:22:50 PM
- Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:00:48 PM
- Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need • GlobeNewswire Inc. • 02/18/2026 01:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/12/2026 09:18:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:00:35 PM
- Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment • GlobeNewswire Inc. • 02/03/2026 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/29/2026 01:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:49:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:13:58 PM
- Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders • GlobeNewswire Inc. • 12/31/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 02:21:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 02:16:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:20 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/03/2025 02:11:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:00:59 PM
- Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2025 08:05:10 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/30/2025 09:17:29 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2025 09:19:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2025 11:58:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2025 09:30:33 PM
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months • GlobeNewswire Inc. • 09/22/2025 12:00:28 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
